Navigation Links
Hologic And Gen-Probe Provide Update On Pending Transaction
Date:7/11/2012

is contingent on the satisfaction of certain conditions set forth in the previously disclosed Commitment Letter for the financing, including that there not having occurred, since December 31, 2011, an Acquired Business Material Adverse Effect (as defined in the Commitment Letter). The closing of each of these financing facilities is expected to take place concurrently with the completion of Hologic's acquisition of Gen-Probe.

Hologic's Preliminary Third Quarter Fiscal 2012 Financial Results:In connection with the commencement of syndication efforts relating to the financing, Hologic today provided preliminary fiscal third quarter 2012 financial results and its full fiscal 2012 revenue and non-GAAP adjusted earnings per share (EPS) outlook.

Based on preliminary financial data, Hologic expects the following for the third quarter of fiscal 2012 as compared to the corresponding period in the prior year: (i) revenues of approximately $470 million as compared to $451.1 million; (ii) non-GAAP adjusted net income in the range of $90 million to $93 million as compared to $85.7 million; (iii) non-GAAP adjusted EPS in the range of $0.34 to $0.35 as compared to $0.32; and (iv) non-GAAP adjusted EBITDA of over $160 million as compared to $154.6 million (non-GAAP adjusted EBITDA is defined as non-GAAP adjusted net income plus: interest expense, net; income taxes; and depreciation and amortization, included in its non-GAAP adjusted net income).

Hologic is also reaffirming the low-end of its full year 2012 revenue guidance of $1.9 billion and its non-GAAP adjusted EPS range of $1.36 to $1.38, as previously provided. This guidance includes Hologic's current operations and does not include the results of Gen-Probe.

Principal factors impacting the Company's third quarter revenue results include a significant acceleration in the shift of orders from 2D digital mammography systems to its new Dimensions 3D breast tomosynthesis systems, as well as customer or
'/>"/>

SOURCE Hologic, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Hologic, Inc. Announces Note Offering
2. Hologic Breast Tomosynthesis (3D Mammography) System Places First in KLAS Annual Survey of Mammography Equipment Users
3. Hologic to Release Third Quarter Fiscal 2012 Operating Results on Monday, July 30, 2012
4. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
5. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
6. Gen-Probe Withdraws from Previously Announced Investor Presentations
7. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
8. ERT Acquires invivodata to Establish the Industrys Most Experienced Provider of Clinical Outcome Assessment Solutions
9. TPI Provides Further Updates on its GMOL Flagship Product
10. PatientPay from Zepherella Now Offers Real-time Pricing, Automatic Payment Reconciliation for Healthcare Providers and Patients
11. Providers of Durable Medical Equipment Ensure Independence and Safety during Extreme Weather and Power Outages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... WHIPPANY, N.J. , Sept. 17, 2014  Bayer ... the National Hemophilia Foundation,s 66 th Annual Meeting, ... , D.C.  The data, which will be shared ... A treatment and patient care. Data will be presented ... display research into treatment modalities in hemophilia A patients, ...
(Date:9/17/2014)... COLUMBUS, Ohio , Sept. 17, 2014 /PRNewswire/ ... Riverside Radiology and Interventional Associates announced today ... Systems to enhance its image sharing capabilities ... case of any network failures. In addition, the ... to help navigate disparate PACS systems to more ...
(Date:9/17/2014)... , Sept. 17, 2014   myMatrixx, a pharmacy and ... that Business Insurance magazine has awarded myMatrixx ... for the third year in a row. ... of Business Insurance  and the Best Companies Group. ... open to all publicly or privately-held insurance industry companies ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2
... - Positive data on subcutaneous administration show potential ... CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Millennium,Pharmaceuticals, Inc. ... the market-leading therapy for patients with,multiple myeloma (MM) ... data include results from a Phase II trial ...
... CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline ... of pazopanib in,advanced or metastatic renal cell ... (STS). These trials were presented at the,43rd ... Clinical Oncology,(ASCO) in Chicago. The results observed ...
Cached Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 7GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 5GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 6GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 7
(Date:9/17/2014)... 2014 In Pretrial Order #139 (Scheduling ... discovery conferences would be beneficial in this [MDL].” Accordingly, ... “At the end of December,” the order further provides, ... additional conferences. , “The plain import of this ... still much to be discussed as these cases progress ...
(Date:9/17/2014)... Dennis Thompson HealthDay ... -- Exposure in the womb to household chemicals known ... developing asthma, Columbia University researchers reported in a new ... risk of developing asthma between age 5 and 11 ... levels of two phthalates (pronounced thal-ates), the researchers found. ...
(Date:9/17/2014)... Scripps Research Institute (TSRI) have devised a new ... against vancomycin-resistant strains of MRSA and other disease-causing ... have not one but two distinct mechanisms of ... resistance quickly. , "This is the prototype of ... clinical use a generation or maybe even two ...
(Date:9/17/2014)... York, New York (PRWEB) September 17, 2014 ... filings involving the Conserve line of metal-on-metal hip ... now underway in U.S. District Court, Northern District ... an updated Case List issued by the U.S. ... 2014, at least 397 product liability claims have ...
(Date:9/17/2014)... Toledo, Ohio (PRWEB) September 17, 2014 ... hearing for today, September 17, 2014, to consider: , ... Testosterone Replacement Therapy (TRT), and, 2. ... of TRT. , With the TRT litigation ongoing, an ... FDA on the dangers of testosterone replacement therapy. Among ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2
... From June Dairy Month through,the State Fair, summer ... June 1, Minnesotans will be able get details about ... mouse. ExploreDairy.com is a,one-stop resource for all the latest ... hardworking dairy farm families., ExploreDairy.com is designed to ...
... 29 The following is a,statement by Matthew L. ... Health Organization,s World No Tobacco Day, to be celebrated,May ... of the global,tobacco epidemic and the urgent need for ... save lives., This year,s theme -- Tobacco-Free Youth: ...
... May 29 The Academy of General,Dentistry (AGD) expresses ... reauthorize the Dental Health Improvement Act (S,3067) for another ... and Benjamin Cardin (D-MD). The intent of the Act ... shortage of dental health,professionals., "Last week was a ...
... Leaders of Indiana and Purdue universities Thursday ... Translational Sciences Institute (CTSI), a medical research initiative ... business and government to swiftly transform discoveries into ... National Institutes of Health has awarded a five-year ...
... The Musculoskeletal Transplant,Foundation (MTF) will provide military hospitals ... joint repair for injured servicemen and,women., Military ... obtaining,tissue used for cartilage transplantation and meniscus grafts ... types of tissue are in high,demand for U.S. ...
... NY) The National Institutes of Health has ... University and Montefiore Medical Center one of its ... million over five years. The grant will support ... Research (ICTR), whose overarching goal is to collaboratively ...
Cached Medicine News:Health News:ExploreDairy.com Debuts With Information on Minnesota Dairy Events, People and Products 2Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 2Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 3Health News:AGD Thanks Senators for Introducing Bill to Reauthorize the Dental Health Improvement Act 2Health News:NIH awards Einstein College of Medicine & Montefiore Medical Center $22M grant 2Health News:NIH awards Einstein College of Medicine & Montefiore Medical Center $22M grant 3
... High Prevalence of Sleep Disordered Breathing (SDB) ... As Prevalent as Diabetes, with Vast Majority ... common form of SDB, affects an estimated ... Only 5% of the OSA patients ...
... The layout is designed efficiently for ... are configured for maximum efficiency. It ... It can be set-up in ... any mobile modality pad and it ...
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... holmium laser combines excellent cutting, ablation ... bloodless procedures. It is also extremely ... bladder stones of all compositions, making ... Because its laser light is transmitted ...
Medicine Products: